TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16339692

Group type: EXPERIMENTAL
Intervention: Serum non-transferrin-bound iron (NTBI) levels measured weekly during transfusion cycles
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Long-term monitoring of NTBI levels
Number of subjects: 15
Study: 12559229

Group type: EXPERIMENTAL
Intervention: SSR-evoking stimulation (sound, voice, and rapid inspiration)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SSR potential distribution measured in 10 subjects
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: SSR potential on the dorsum of the hand
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Estimated equivalent current dipole (ECD)
Number of subjects: 22
Study: 10536647

Group type: EXPERIMENTAL
Intervention: Waist-Hip Ratio (WHR)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control for genetic influences
Number of subjects: 263
Study: 8683231

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11) at a dose of 145 mg/m2 administered as a 90-minute infusion with G-CSF and antidiarrheal support
Number of subjects: 40
Study: 1806467

Group type: COMPARATOR
Intervention: Parlodel R (conventional bromocriptine) 2.5 mg b.i.d. for 2 weeks, then doubled for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Parlodel SRO (slow-release bromocriptine) 5 mg once daily for 2 weeks, then doubled for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Parlodel SRO (slow-release bromocriptine) 2.5-10 mg daily for 6 months
Number of subjects: 12
Study: 6410266

Group type: EXPERIMENTAL
Intervention: Structured psychotherapeutic counselling during detoxification
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard detoxification without counselling
Number of subjects: 25
Study: 29224960

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 57
Study: 28077379

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Polydextrose
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) and Polydextrose
Number of subjects: 75
Study: 25975969

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg bolus over 5 minutes, followed by 1.5 mg/kg/h continuous infusion until end of surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 0
Study: 24093844

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg twice a day
Number of subjects: 19102

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 19102
Study: 20364698

Group type: EXPERIMENTAL
Intervention: RFC (rituximab, fludarabine, and cyclophosphan)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: FCM (fludarabine, cyclophosphan, and mitoxantrone)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: FC (fludarabine and cyclophosphan)
Number of subjects: 229
Study: 19146054

Group type: EXPERIMENTAL
Intervention: Particulate autogenous bone and platelet-rich plasma (PRP)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Particulate autogenous bone alone
Number of subjects: 4
Study: 16388984

Group type: EXPERIMENTAL
Intervention: CMV gB vaccine
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 12804020

Group type: EXPERIMENTAL
Intervention: Algal extract in safflower oil (2 mg of astaxanthin each, 3 gelcaps per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (safflower oil only, 3 gelcaps per day)
Number of subjects: 35
Study: 10826575

Group type: EXPERIMENTAL
Intervention: 100 mg SR49059
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 mg SR49059
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8829862

Group type: EXPERIMENTAL
Intervention: Stylet retained for entire intubation procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stylet removed after bronchial cuff passed vocal cords
Number of subjects: 60
Study: 1642202

Group type: EXPERIMENTAL
Intervention: Once-a-day morning administration of 40 mg famotidine
Number of subjects: 179

Group type: COMPARATOR
Intervention: Once-a-day bedtime administration of 40 mg famotidine
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 179

Group type: COMPARATOR
Intervention: Bedtime group
Number of subjects: 179
Study: 6192636

Group type: EXPERIMENTAL
Intervention: Alternating-pressure air-mattresses
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Water-mattresses
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study: 29706701

Group type: EXPERIMENTAL
Intervention: Flexion‐distraction and drop techniques
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal decompression therapy
Number of subjects: 30
Study: 26991814

Group type: EXPERIMENTAL
Intervention: PC-Active
Number of subjects: 414

Group type: COMPARATOR
Intervention: PC-Control
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: PC-Combined
Number of subjects: 414

Group type: COMPARATOR
Intervention: SD
Number of subjects: 414
Study: 24506194

Group type: EXPERIMENTAL
Intervention: 8% lidocaine (LDC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PBO) saline
Number of subjects: 24
Study: 22666096

Group type: EXPERIMENTAL
Intervention: PMMA + FNB (FNB group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: PMMA only (PMMA group)
Number of subjects: 39
Study: 19656349

Group type: EXPERIMENTAL
Intervention: New uniform restrictive transfusion policy
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard care policy
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: New transfusion policy in two hospitals
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: New transfusion policy in third hospital
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Both policies
Number of subjects: 603
Study: 18378001

Group type: EXPERIMENTAL
Intervention: Psychotic features in patients with bipolar mania
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: PANSS items (grandiosity, delusions, lack of judgment/insight, excitement, suspiciousness/persecution, hostility)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Grandiosity symptoms of delusional proportions
Number of subjects: 515
Study: 15785149

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (INR 2.0-3.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ximelagatran (fixed dose)
Number of subjects: 0
Study: 11851727

Group type: EXPERIMENTAL
Intervention: d-penicillamine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9950380

Group type: COMPARATOR
Intervention: Standard open technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rapid Four-Step Technique (RFST)
Number of subjects: 30
Study: 7778533

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delapril 15 mg twice daily
Number of subjects: 30
Study: 2318113

Group type: EXPERIMENTAL
Intervention: Threefold basal immunosuppression (low-dose ciclosporin, azathioprine, and prednisolone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fourfold basal immunosuppression (with additional poly- or monoclonal antibodies)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Additional antirejection treatment with poly- or monoclonal antibodies
Number of subjects: 100
Study: 7350888

Group type: EXPERIMENTAL
Intervention: Electronic intravenous (IV) rate controller
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard roller clamp
Number of subjects: 0
Study: 31915038

Group type: EXPERIMENTAL
Intervention: High-protein diet and resistance training combination
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional low-fat diet
Number of subjects: 90

Group type: COMPARATOR
Intervention: High-protein diet
Number of subjects: 90
Study: 31030282

Group type: EXPERIMENTAL
Intervention: Older adults during speech production in response to temporally unpredictable stimuli
Number of subjects: 2

Group type: COMPARATOR
Intervention: Younger adults during speech production in response to temporally unpredictable stimuli
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Older adults during button press motor reaction time tasks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Younger adults during button press motor reaction time tasks
Number of subjects: 2
Study: 27458993

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Artesunate combination therapy (ACT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ACT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quinine vs ACT
Number of subjects: 100
Study: 25597369

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 120
Study: 23521105

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme (Supreme) at 60 cm H(2)O
Number of subjects: 180

Group type: COMPARATOR
Intervention: Laryngeal mask airway Unique (laryngeal mask airway-U) at 60 cm H(2)O
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme (Supreme) at 40 cm H(2)O
Number of subjects: 180

Group type: COMPARATOR
Intervention: Laryngeal mask airway Unique (laryngeal mask airway-U) at 40 cm H(2)O
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme (Supreme)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Laryngeal mask airway Unique (laryngeal mask airway-U)
Number of subjects: 180
Study: 21558397

Group type: EXPERIMENTAL
Intervention: Topically applied CUR61414 (0.09%, 0.35%, 1.1%, and 3.1%) for up to 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical CUR61414 in preclinical studies
Number of subjects: 0
Study: 19465442

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microg twice daily from a Diskus inhaler)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral prednisone (30 mg daily)
Number of subjects: 41
Study: 17525499

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial and second-screening systems
Number of subjects: 0
Study: 15202770

Group type: EXPERIMENTAL
Intervention: Acute oral lorazepam (0.5 mg or 1 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11423918

Group type: EXPERIMENTAL
Intervention: BIA (bioelectrical impedance analysis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: DXA (dual energy X-ray absorptiometry)
Number of subjects: 27

Group type: COMPARATOR
Intervention: BIA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: BIA and DXA
Number of subjects: 27
Study: 9537307

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of bombesin (0.09 nmol/kg ideal weight/h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 14
Study: 7625786

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 12
Study: 2225536

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone (DAK)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide (Kenalogue)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone‐17‐valerate cream (Betnovate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol proprionate cream (Dermovate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: base cream
Number of subjects: 10
Study: 213459

Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 360

Group type: COMPARATOR
Intervention: Caring persons' reactions
Number of subjects: 360
Study: 31686785

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 79

Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 79
Study: 29122156

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg intravenously every 4 weeks for up to 24 months
Number of subjects: 1051
Study: 25744962

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) plus Healthy Lifestyles intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) plus predominantly telephone-based intervention
Number of subjects: 235
Study: 23512860

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) on statin therapy
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Usual care on statin therapy
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) not on statin therapy
Number of subjects: 1431
Study: 21545068

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 19704175

Group type: EXPERIMENTAL
Intervention: TMC278 25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TMC278 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TMC278 150 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TMC278 (overall)
Number of subjects: 36
Study: 16916429

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion before stress
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 13129464

Group type: EXPERIMENTAL
Intervention: FOS-supplemented infant cereal (0.75 g FOS per serving)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study: 10574519

Group type: EXPERIMENTAL
Intervention: Contingency contracting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paid participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial weight loss program
Number of subjects: 0
Study: 8912022

Group type: EXPERIMENTAL
Intervention: Artificial Neural Net classifier
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayesian classifier
Number of subjects: 0
Study: 1987410

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 123
Study: 6347749

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5-1 mg b.i.d. for 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2582325

Group type: EXPERIMENTAL
Intervention: Intensive cyclic therapy using either the same drugs of the induction regimen or rotating combinations of alternative drugs (e.g., mAMSA, 5-AZA, HD-Ara C)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Maintenance arm I
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Maintenance arm II
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Induction treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Induction or maintenance treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Remission duration or survival
Number of subjects: 266
Study: 29190004

Group type: EXPERIMENTAL
Intervention: Tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fixed doses of the same regimen (group B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: TAC regimen (group C)
Number of subjects: 124
Study: 27392509

Group type: EXPERIMENTAL
Intervention: Left Ventricular Mass
Number of subjects: 100
Study: 24536058

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Corn-soy blend plus (CSB+)
Number of subjects: 524
Study: 22849958

Group type: EXPERIMENTAL
Intervention: Mini-open muscle splitting incision (MSI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hand-assisted laparoscopic technique (HAL)
Number of subjects: 50
Study: 20407435

Group type: EXPERIMENTAL
Intervention: Cognitive tasks designed to improve reasoning, memory, planning, visuospatial skills, and attention, trained several times each week for six weeks.
Number of subjects: 11430
Study: 18199863

Group type: EXPERIMENTAL
Intervention: Etanercept (0.8 mg/kg, max 50 mg)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Etanercept (after 24 weeks of open-label treatment)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo (after 24 weeks of open-label treatment)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo (during withdrawal from week 36 to week 48)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Etanercept (open-label treatment)
Number of subjects: 211
Study: 15928526

Group type: EXPERIMENTAL
Intervention: Usual care plus a kit of nonpharmacologic strategies
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study: 12575908

Group type: EXPERIMENTAL
Intervention: Whey preload (48 g, 1700 kJ liquid preload)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey test meal
Number of subjects: 0
Study: 10232292

Group type: EXPERIMENTAL
Intervention: Active catecholamine depletion via oral administration of 5 g alpha‐methylparatyrosine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham catecholamine depletion via oral administration of 250 mg diphenhydramine hydrochloride
Number of subjects: 27
Study: 8734351

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1000 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 16
Study: 1746734

Group type: EXPERIMENTAL
Intervention: Manikin-only training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manikin-plus-cadaver training
Number of subjects: 0
Study: 7105826

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/amiloride
Number of subjects: 70

Group type: COMPARATOR
Intervention: cyclopenthiazide/potassium
Number of subjects: 70
Study: 31575569

Group type: EXPERIMENTAL
Intervention: Self-monitoring only (self-weighing and activity tracker)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Self-regulation and motivation
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Emotion regulation
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Combined self-regulation, motivation and emotion regulation
Number of subjects: 1627

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 1627
Study: 28834385

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin-C (MMC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Deep sclerectomy without mitomycin-C (non-MMC)
Number of subjects: 37
Study: 27112475

Group type: EXPERIMENTAL
Intervention: Arterial infusion with 8 ml of 1% methylene blue
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group without artery infusion
Number of subjects: 112
Study: 25530465

Group type: EXPERIMENTAL
Intervention: Interrupted Force (IF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous Force (CF)
Number of subjects: 30
Study: 22627477

Group type: EXPERIMENTAL
Intervention: PF‐04523655 (50 to 3000 μg)
Number of subjects: 54
Study: 19067709

Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 microg g(‐1) plus betamethasone 0.5 mg g(‐1))
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.5 mg g(‐1)
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg g(‐1)
Number of subjects: 1417
Study: 17976797

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol ingested 1.5 h before oxycodone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 mg immediate-release oxycodone orally
Number of subjects: 10
Study: 16356868

Group type: EXPERIMENTAL
Intervention: Aciclovir (ACV) plus recombinant interferon-beta (rIFN-beta)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aciclovir (ACV) plus placebo
Number of subjects: 59
Study: 12593694

Group type: COMPARATOR
Intervention: Cefazolin 1 g intravenously before operation and 1 g intravenously at the end of cardiopulmonary bypass (Group 1)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g intravenously before operation, followed by continuous intravenous infusion at 20 mg/min throughout surgery (Group 2)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cefazolin 3 g intravenously before operation, followed by continuous intravenous infusion at 15 mg/min throughout surgery (Group 3)
Number of subjects: 137
Study: 10491209

Group type: EXPERIMENTAL
Intervention: Vitamin D receptor genotype (TaqI, ApaI)
Number of subjects: 9704

Group type: COMPARATOR
Intervention: Vitamin D receptor polymorphisms (TaqI and ApaI)
Number of subjects: 9704
Study: 8708714

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg three times daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES, 1 mg three times daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 92
Study: 1678800

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Adjuvant locoregional radiotherapy
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1113
Study: 6293321

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen producing less depression and fatigue
Number of subjects: 77

Group type: COMPARATOR
Intervention: Other chemotherapy regimen
Number of subjects: 77
Study: 12185396

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg and 60 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30652031

Group type: EXPERIMENTAL
Intervention: PPARG2 Pro12Ala Ala carriers
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined genotypes ProAla + AlaAla and GC + CC
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PPARG2 Ala allele carriers (ProAla + AlaAla and GG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: IL6 ‐174G >C polymorphism
Number of subjects: 150